scholarly journals Synthesis and Evaluation of a Targeted Nanoglobular Dual-Modal Imaging Agent for MR Imaging and Image-Guided Surgery of Prostate Cancer

2013 ◽  
Vol 31 (6) ◽  
pp. 1469-1476 ◽  
Author(s):  
Mingqian Tan ◽  
Zhen Ye ◽  
Daniel Lindner ◽  
Susann M. Brady-Kalnay ◽  
Zheng-Rong Lu
Keyword(s):  
Prostate Cancer ◽  
Mr Imaging ◽  
Imaging Agent ◽  
Image Guided Surgery ◽  
Guided Surgery ◽  
Image Guided

Abstract CT018: Image guided surgery for tumor agnostic detection of solid tumors using the pH activated micellar imaging agent ONM-100: The Shine study

2019 ◽  
Author(s):  
Pieter J. Steinkamp ◽  
Floris J. Voskuil ◽  
Marjory Koller ◽  
Bert van der Vegt ◽  
Jan J. Doff ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Imaging Agent ◽  
Image Guided Surgery ◽  
Guided Surgery ◽  
Image Guided

MR Imaging–Controlled Focused Ultrasound Ablation: A Noninvasive Image-Guided Surgery

2005 ◽  
Vol 13 (3) ◽  
pp. 545-560 ◽  
Author(s):  
Ferenc A. Jolesz ◽  
Kullervo Hynynen ◽  
Nathan McDannold ◽  
Clare Tempany
Keyword(s):  
Mr Imaging ◽  
Focused Ultrasound ◽  
Image Guided Surgery ◽  
Guided Surgery ◽  
Image Guided ◽  
Ultrasound Ablation ◽  
Focused Ultrasound Ablation

Image-guided surgery for tumor agnostic detection of solid tumors using the pH-activated micellar imaging agent ONM-100.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3068-3068 ◽  
Author(s):  
Floris Jan Voskuil ◽  
Pieter Jan Steinkamp ◽  
Marjory Koller ◽  
Bert van der Vegt ◽  
Jan Johannes Doff ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Fluorescent Imaging ◽  
Activation Mechanism ◽  
Imaging Agent ◽  
Image Guided Surgery ◽  
Pharmacokinetic Data ◽  
Guided Surgery ◽  
Image Guided ◽  
Fluorescence Images

3068 Background: ONM-100, a micelle-based polymer imaging agent conjugated to indocyanine green (ICG) and with an exquisitely pH-sensitive binary activation mechanism, may be used for tumor detection. ONM-100 micelles dissociate in acidic environments resulting in activation of the fluorescent ICG tag. As nearly all solid cancer types are acidotic, ONM-100 has the potential to act as a broadly indicated tumor agnostic imaging agent. This first-in-human study investigates the safety and feasibility of ONM-100 as a tumor agnostic imaging agent for intra-operative fluorescent imaging of various solid tumors. Methods: ONM-100 was IV administered 24±8h prior to surgery in a dose escalation scheme (0.1-1.2mg/kg). Patients with histopathologically confirmed breast cancer (BC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and esophageal cancer (EC) were included. Blood was drawn to assess safety and pharmacokinetic data. Intra-operative fluorescence images were collected before and after tumor excision. Post-excision fluorescence images were obtained from serially sliced specimens and correlated with standard histopathological assessment. Results: 30 patients (11 BC, 13 HNSCC, 3 EC, 3 CRC) were enrolled. No ONM-100 related serious adverse events were observed and the agent was well-tolerated. A strong and sharply demarcated fluorescent signal was observed in all patients with vital tumor tissue (median CNR ranging 1.85-14.05) which correlated with tumor on final histopathology. HNSCC and superficially located BC as well as peritoneal metastasis could be clearly visualized in vivo during surgery. In four patients (BC and HNSCC), perioperatively, tumors otherwise unnoticed by the surgeons were detected on the margin or wound bed using fluorescence imaging. Additionally, two BC tumor lesions were detected that were missed by conventional pre-operative imaging and pathological assessment. Conclusions: ONM-100 appears to be safe and enables fluorescent visualization of tumors both in vivo and ex vivo. The first-in-human data demonstrate the feasibility for potential use of ONM-100 for image guided surgery, margin assessment and detection of occult disease. Clinical trial information: NTR 7085.

scholarly journals Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time

2015 ◽  
Vol 22 (6) ◽  
pp. 1403-1412 ◽  
Author(s):  
Geoffrey A. Sonn ◽  
Andrew S. Behesnilian ◽  
Ziyue Karen Jiang ◽  
Kirstin A. Zettlitz ◽  
Eric J. Lepin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Real Time ◽  
Image Guided Surgery ◽  
Prostate Stem Cell Antigen ◽  
Cell Antigen ◽  
Guided Surgery ◽  
Image Guided ◽  
Fluorescent Image ◽  
Mouse Prostate

Evaluation of factors predicting accurate resection of high-grade gliomas by using frameless image-guided stereotactic guidance

2003 ◽  
Vol 14 (2) ◽  
pp. 1-4 ◽  
Author(s):  
Ronald Benveniste ◽  
Isabelle M. Germano
Keyword(s):  
Mr Imaging ◽  
Extent Of Resection ◽  
Image Guided Surgery ◽  
High Grade ◽  
Brain Shift ◽  
Patient Age ◽  
Guided Surgery ◽  
Image Guided ◽  
Patient Âgé ◽  
High Grade Gliomas

Object Frameless image-guided stereotaxy is often used in the resection of high-grade gliomas. The authors of several studies, however, have suggested that brain shift may occur intraoperatively and result in inaccurate resection. To determine the usefulness of frameless stereotactic image-guided surgery of high-grade gliomas, the authors correlated factors predictive of brain shift, such as tumor size, periventricular location, and patient age (as an indicator of brain atrophy) with the extent of resection. Methods Inclusion criteria included the following: 1) stereotactic volumetric craniotomy for resection of tumor; 2) histologically proven high-grade glioma; 3) preoperative magnetic resonance (MR) imaging demonstration of an enhancing portion of tumor; 4) postoperative MR imaging within 48 hours to assess the extent of resection; and 5) preoperative intention to perform gross-total resection of the enhancing tumor. Fifty-four patients met these criteria between September 1997 and November 2002. Accurate resection was considered to be indicated by a lack of nodular enhancement on postoperative Gd-enhanced MR images obtained within 48 hours of surgery. Frameless stereotactic image-guided surgery resulted in the successful resection of 46 (85%) of 54 high-grade gliomas. Accurate resection was significantly more likely with tumors less than 30 ml in volume than with those greater than 30 ml (93 and 58%, respectively [p < 0.05]). In addition, small periventricular tumors were associated with significant less successful resection compared with nonperiventricular tumor (77 and 96%, respectively [p = 0.5]). Patient age did not affect the likelihood of successful resection. Conclusions Frameless image-guided stereotactic techniques can be reliably used for accurate resection of high-grade gliomas when the tumor is less than 30 ml in volume and not adjacent to the ventricular system. In cases involving tumors larger in volume or located near the ventricles, intraoperative ultrasonography or MR imaging updates should be considered.

Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer

2019 ◽  
Vol 22 (1) ◽  
pp. 85-93 ◽  
Author(s):  
Amerigo Pagoto ◽  
Francesca Garello ◽  
Giada Maria Marini ◽  
Martina Tripepi ◽  
Francesca Arena ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Near Infrared ◽  
Image Guided Surgery ◽  
Near Infrared Fluorescence ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Guided Surgery ◽  
Image Guided ◽  
Fluorescence Dye
Sign in / Sign up

Export Citation Format

Share Document